EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

N6-methyladenosine Methyltransferase METTL3 Enhances PTGER2 Expression to Increase Ovarian Cancer Stemness and Chemoresistance

Yi-Bin Lin, Ben-Hua Xu

Frontiers in Bioscience-Landmark · 14.09.2023 · 28 (9)

DOI: 10.31083/j.fbl2809199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 14.09.2023. Verfasst von Yi-Bin Lin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, 350014 Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Receptors, Prostaglandin E, EP2 Subtype, Ovarian Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fujian Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ovarian cancer is the second leading cause of gynecologic cancer-associated deaths. Cancer stemness and chemoresistance are responsible for ovarian cancer metastasis and the poor prognosis of patients. In this study, we determined the function of N6-methyladenine (m6A) RNA methylation and prostaglandin E receptor 2 (PTGER2) in ovarian cancer progression.

Methods

The m6A RNA methylation-associated PTGER2 in ovarian cancer was identified using bioinformatics analysis. The role of PTGER2 in ovarian cancer was elucidated in cell lines and clinical samples with cellular and molecular experiments.

Results

In this investigation, bioinformatics analysis based on a public cancer database was used to elucidate the impact of m6A modification on the prognosis of patients with ovarian cancer. Moreover, PTGER2 was identified as a potential oncogene associated with the distant metastasis of ovarian cancer and poor patient prognosis. Interestingly, PTGER2 expression was experimentally shown to be enhanced by N6-adenosine-methyltransferase 70 kDa subunit (METTL3)-mediated m6A modification. In addition, PTGER2 enhanced cancer stem cell self-renewal properties, the epithelial-mesenchymal transition, and DNA damage repair, thus potentiating cell stemness, therapy resistance to carboplatin, proliferation, and metastasis of ovarian cancer. Importantly, PTGER2 expression in clinical samples was associated with distant metastasis, predicted poor patient prognosis, and independently served as a prognostic predictor in ovarian cancer.

Conclusions

Our work defines PTGER2 as an oncogene and reveals that PTGER2 is a prognostic predictor and novel therapeutic target for the management of ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Prostaglandin E, EP2 SubtypeOvarian NeoplasmsHumansFemaleDrug Resistance, NeoplasmCell Line, TumorMethyltransferasesAdenosineRNA

Stichwörter der Autor:innen

N6-methyladenosinePTGER2chemoresistanceovarian cancerstemness

Substanzen

Receptors, Prostaglandin E, EP2 SubtypeMethyltransferasesAdenosineRNAMETTL3 protein, humanPTGER2 protein, human

Autor:innen und Institutionen

  • Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, 350014 Fuzhou, Fujian, China.
  • Department of Radiation Oncology, Fujian Medical University Union Hospital, 350001 Fuzhou, Fujian, China.
  • Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors (Fujian Medical University), 350001 Fuzhou, Fujian, China.
  • Clinical Research Center for Radiology and Radiotherapy of Fujian Province (Digestive, Hematological and Breast Malignancies), 350001 Fuzhou, Fujian, China.

Förderung

  • Fujian Medical University

Zitieren

APA

Lin, Y. B., & Xu, B. H. (2023). N6-methyladenosine Methyltransferase METTL3 Enhances PTGER2 Expression to Increase Ovarian Cancer Stemness and Chemoresistance. Frontiers in Bioscience-Landmark, 28(9). https://doi.org/10.31083/j.fbl2809199

Vancouver

Lin YB, Xu BH. N6-methyladenosine Methyltransferase METTL3 Enhances PTGER2 Expression to Increase Ovarian Cancer Stemness and Chemoresistance. Frontiers in Bioscience-Landmark. 2023;28(9). doi:10.31083/j.fbl2809199

BibTeX
@article{Lin2023,
  author = {Lin, Yi-Bin and Xu, Ben-Hua},
  title = {N6-methyladenosine Methyltransferase METTL3 Enhances PTGER2 Expression to Increase Ovarian Cancer Stemness and Chemoresistance},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2023},
  volume = {28},
  number = {9},
  doi = {10.31083/j.fbl2809199}
}
Kostenlos starten →